Clinical Trials Directory

Trials / Terminated

TerminatedNCT02223494

Safety of Terbogrel in Patients With Primary Pulmonary Hypertension

An Open-label, Long-term Safety Evaluation of Terbogrel in Patients With Primary Pulmonary Hypertension

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
33 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Study to assess the safety of terbogrel during open-label, long-term treatment in medically stable or improving patients with primary pulmonary hypertension who have completed the 12-week, double-blind randomized trial of terbogrel (protocol 528.19)

Conditions

Interventions

TypeNameDescription
DRUGTerbogrel

Timeline

Start date
1998-10-01
Primary completion
2000-03-01
First posted
2014-08-22
Last updated
2014-08-22

Source: ClinicalTrials.gov record NCT02223494. Inclusion in this directory is not an endorsement.